Saha et al. [38] showed that the triple combination of OHSV G47Δ expressing murine IL-12 with anti-CTLA-4 and anti-PD-1 antibodies extended survival with no pathological symptoms up to 9 months in a mouse glioma model. This evidence concerns the gene CTLA4 and central nervous system cancer.